このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cyxone 将来の成長

Future 基準チェック /06

Cyxoneの収益と利益はそれぞれ年間122.2%と20.2%減少すると予測されていますが、EPS は年間6.9% 減少すると予測されています。

主要情報

-20.2%

収益成長率

-6.9%

EPS成長率

Biotechs 収益成長	39.1%
収益成長率	-122.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	27 Feb 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Dec 12

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

Aug 29

業績と収益の成長予測

OM:CYXO - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-39	-37	-37	1
12/31/2025	N/A	-38	-35	-35	1
12/31/2024	N/A	-28	-26	-26	1
3/31/2024	5	-22	-25	-18	N/A
12/31/2023	5	-23	-26	-19	N/A
9/30/2023	6	-17	-32	-18	N/A
6/30/2023	6	-23	-33	-21	N/A
3/31/2023	8	-31	-46	-36	N/A
12/31/2022	6	-42	-49	-41	N/A
9/30/2022	N/A	-54	-51	-50	N/A
6/30/2022	N/A	-54	-55	-54	N/A
3/31/2022	N/A	-53	-45	-44	N/A
12/31/2021	N/A	-45	-44	-43	N/A
9/30/2021	N/A	-43	-43	-43	N/A
6/30/2021	N/A	-45	-39	-44	N/A
3/31/2021	N/A	-47	-45	-45	N/A
12/31/2020	N/A	-49	-45	-45	N/A
9/30/2020	N/A	-46	-43	-43	N/A
6/30/2020	N/A	-46	-46	-41	N/A
3/31/2020	N/A	-39	-36	-36	N/A
12/31/2019	N/A	-35	-35	-35	N/A
9/30/2019	N/A	-47	-57	-43	N/A
6/30/2019	N/A	-39	-49	-36	N/A
3/31/2019	N/A	-36	-49	-35	N/A
12/31/2018	N/A	-32	-43	-30	N/A
9/30/2018	N/A	-14	-19	-13	N/A
6/30/2018	N/A	-11	-16	-10	N/A
3/31/2018	N/A	-10	-13	-7	N/A
12/31/2017	N/A	-9	N/A	-5	N/A
9/30/2017	0	-7	N/A	-6	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-5	N/A	-5	N/A
12/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	0	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CYXO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYXO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CYXO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYXO来年は収益がないと予測されています。

高い収益成長: CYXO来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CYXOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cyxone 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to kr4.20

Price target increased to kr16.00

Recent updates

New major risk - Share price stability

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Price target decreased to kr4.20

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Price target increased to kr16.00

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: kr5.03

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: kr5.51

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: kr5.52

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - kr7.48

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘